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Abstract
Background: It is expected that physical dose deposition properties render charged particle dose distributions
sensitive to targeting uncertainties. Purpose of this work was to investigate the robustness of scanned-beam particle
therapy plans against setup errors for different optimization modalities, beam setups and ion species.
Material andmethods: For 15 patients with skull base tumors, localized in regions of severe tissue density
heterogeneity, scanned lateral-opposed-beam treatment plans were prepared with the treatment planning system
TRiP98, employing different optimization settings (single- and multiple-field modulation) and ion species (carbon ions
and protons). For 10 of the patients, additional plans were prepared with individually selected beam setups, aiming at
avoiding severe tissue heterogeneities. Subsequently, multiple rigid positioning errors of magnitude 1–2 mm (i.e.
within planning target expansion) were simulated by introducing a shift of the irradiation fields with respect to the
computed tomography (CT) data and recomputing the plans.
Results: In presence of shifts, in carbon ion plans using a lateral-opposed beam setup and fulfilling clinical healthy
tissue dose constraints, the median reduction in CTV V95% was up to 0.7 percentage points (pp) and 3.5 pp, for shifts of
magnitude 1 mm and 2 mm respectively, however, in individual cases, the reduction reached 5.1 pp and 9.7 pp. In the
corresponding proton plans similar median CTV V95% reductions of up to 0.9 pp (1 mm error) and 3.4 pp (2 mm error)
were observed, with respective individual-case reductions of at most 3.2 pp and 11.7 pp. Unconstrained plans offered
slightly higher coverage values, while no relevant differences were observed between different field modulation
methods. Individually selected beam setups had a visible dosimetric advantage over lateral-opposed beams, for both
particle species. While carbons provided more conformal plans and generally more advantageous absolute dose
values, in presence of setup errors, protons showed greater dosimetric stability, in most of the investigated scenarios.
Conclusion: Residual patient setup errors may lead to substantial dose perturbation in scanned-beam particle
therapy of skull base tumors, which cannot be dealt with by planning target expansion alone. Choice of irradiation
directions avoiding extreme density heterogeneities can improve plan stability against such delivery-time
uncertainties.
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Background
The so-called inverse depth-dose profile and the sharp
lateral penumbra make charged particles, like protons
and carbon ions, apt for high-precision dose-escalated
radiotherapy, e.g. in the treatment of intracranial tumors,
due to the direct vicinity of critical structures [1,2]. Car-
bon ions offer additionally an enhanced relative biological
effectiveness (RBE) [1].
Yet, based on physical properties of dose deposition by
charged particle beams, it is expected that these advan-
tages come to the price of greater sensitivity to delivery-
time targeting uncertainties as both, the geometrical
miss due to sharp lateral gradients and the displacement
of the density heterogeneity interfaces within the treat-
ment field, may result in delivered dose deterioration,
which may not be completely dealt with by planning tar-
get expansion [3]. For scanned-beam intensity-modulated
treatments, which can produce steep dose gradients and
often rely on them to achieve their superior confor-
mity, the problem of dosimetric robustness is likely of
greater concern [3]. In this respect, a role may also be
played by the physical dose modulation typically present
in biologically-optimized carbon ion treatment plans,
on account of the variable RBE, depending on multiple
factors, including local dose [4].
The importance of the selection of an optimal plan,
not only in terms of clinical dosimetric quality (target
dose coverage versus normal tissue sparing), but also tak-
ing into account robustness, i.e. degree of sensitivity of
the plan to the uncertainties involved in the treatment
process, has been recognized by the ICRU [5] and empha-
sized, more recently, by Cantone et al. [6]. One method
to assess the relevance of the above-mentioned dosimetric
effects and to support clinical decision making is recom-
putation of treatment plans in geometries simulating the
expected errors. Jäkel et al. [7] reported this procedure as
part of patient-specific quality assurance for scanned car-
bon ion therapy, while a method for the evaluation of such
tests was demonstrated by Lomax [3].
While the dosimetric robustness of particle therapy
treatment plans has been extensively studied for other
indications, e.g. prostate tumors [8,9], the published liter-
ature on cranial tumors is sparse. Recently, Hopfgartner
et al. [10] investigated the robustness of proton treat-
ment plans with respect to interfractional setup uncer-
tainties, while the only previous work addressing this
issue for carbon ions, a conference communication by
Ellerbrock et al. [11], focused primarily on the eval-
uation of the multiple-field optimization approach, i.e.
full intensity modulation (typically referred to as IMPT),
as opposed to the single-field uniform-dose (SFUD)
approach.
In this study we apply extensive plan recomputation,
on a cohort of patients with skull base tumors, in order
to systematically assess dosimetric robustness of scanned
beam charged particle treatment plans in presence of
setup errors and critical heterogeneities for (1) various
plan optimization modalities, (2) different beam setups
and (3) two particle species (carbon ions and protons).
Material andmethods
Patient data
The data of 15 patients with skull base tumors (P1–P15)
treated at our institution with intensity-modulated
radiotherapy (IMRT) (P1, P13) or with stereotactic radio-
therapy (SRT) (remaining) were chosen, with tumor local-
ization typical for particle therapy indications (chordoma,
chondrosarcoma, adenocystic carcinoma), in areas of
high density heterogeneity and close to dose limiting
structures.
Planning computed tomographies (CT) were acquired,
without contrast medium, with in-slice resolution and
slice thickness of 0.98 mm/pixel and 3 mm (P1, P13),
0.59 mm/pixel and 3 mm (P2, P11–P12) and 0.59
mm/pixel and 2.5 mm (remaining). The original clinical
target volume (CTV) and organs at risk (OAR) con-
tours, retained for the study, were delineated in the
Pinnacle3 (Philips Healthcare, Best, The Netherlands)
treatment planning system (TPS) for IMRT cases and in
the Virtuos (Stryker-Leibinger, Freiburg, Germany) sys-
tem for SRT cases, excluding unnecessary air cavities
from target volumes. The median (range) CTV volume
was 45.2 (15.6–90.7) cm3. The planning target volume
(PTV) was defined, similarly to Orecchia et al. [2], by
applying a margin of 2 mm in anteroposterior (AP) and
mediolateral (LR) direction and of 2.5–3 mm in superoin-
ferior (SI) direction, depending on CT slice thickness. The
CTV-to-PTV expansion was performed on a single TPS
to avoid potential inter-system algorithm variability. A
contour separating the skin surface from the immobiliza-
tion mask was added and densities outside it overridden
with air, to excludemask-specific heterogeneities from the
investigation.
Following our institutional ethics procedures, all pa-
tients were informed of potential retrospective research
use of their data and given the choice to opt out. The data
presented in this manuscript do not reveal, either directly
or indirectly, the patients’ identities.
Treatment planning
Carbon ion and proton treatment plans for raster-
scanning delivery [12] were prepared using the TRiP98
planning system (GSI Helmholtzzentrum für Schwerio-
nenforschung, Darmstadt, Germany) [4,13]. The conver-
sion program dcm2trip, developed at our institution and
distributed with TRiP98, was used to convert the DICOM
data (CT images and structure sets) to the VOXELPLAN
format used by TRiP98 [14].
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The local effect model LEM I was used for calculation
of the RBE of carbon ions (α/β = 2 Gy, threshold dose
Dt = 30 Gy, nuclear radius r = 4.5 μm), while a fixed
value of 1.1 was employed for proton RBE.
The prescription dose was set to 60–63 Gy(RBE) deliv-
ered in 20–21 fractions for carbon ion plans and 64–
74 Gy(RBE) in 32–37 fractions for proton plans similarly
to Nikoghosyan et al. [15,16] and to Ares et al. [17]. The
planning objective was to deliver at least 95% of the pre-
scription dose to 95% of the PTV (V95% ≥ 95%) and at
least 95% of the prescription dose to 98% of the CTV vol-
ume (V95% ≥ 98%), if possible without compromising
organs at risk.
Also OAR dose constraints were derived from the pro-
tocols adopted in the above-mentioned studies. A maxi-
mum dose (Dmax) constraint at 54 Gy(RBE) was defined
for optic nerves, optic chiasm and brainstem, however, the
brainstem surface (1% of volume) abutting the PTV was
allowed to receive a dose of up to 60 Gy(RBE) [15,16]. In
proton plans, the corresponding limits were 60 Gy(RBE)
and 63 Gy(RBE) [17].
For each patient two carbon ion treatment plans and
a proton plan were prepared using two lateral-opposed
beams (LR), reflecting the geometry typically available at
fixed-nozzle carbon ion facilities.
The two carbon ion plans had, respectively, OAR
constraints requiring per-field modulation (single-field
optimization, denoted as sc) and full plan modulation
(multiple field optimization, denoted as mc). The latter
modality was also used in proton planning. Additionally,
for comparison, plans without OAR constraints (uncon-
strained mode, denoted as uc) were prepared for both ion
species.
Finally, for selected patients (n = 10), carbon ion and
proton plans using full modulation (mc) were prepared
using two beams with individually selected directions. By
visually analyzing potential beam directions, those were
selected that appeared tominimize the presence of density
interfaces along the entrance channels, that could intro-
duce range variations in case of setup errors. These beam
setups, referred to as robust (ROB) in the remainder of the
text, employ a range of isocentric couch rotations (yaw)
towards cranial direction, combined, in the majority of
cases, with beam inclination about the longitudinal axis.
Such gantry-rotation-like setups are enabled, at our facil-
ity, by combined use of 45-degree-inclined beam lines,
6-degree-of-freedom robotic couches (enabling patient
roll and pitch up to 15 degrees with proper immo-
bilization) and, when required, individualized solutions
(immobilization with an advantageous head rotation or
treatment in prone position).
At synchrotron based facilities, the available pencil
beam transversal widths (spot sizes) in air at the treatment
room isocenter are a function of the beam energy [13]. For
carbon ion plans pencil beam full-width at half-maximum
varied from 7.5 mm to 5.0 mm, as specified for the
required energy range in the TPS synchrotron library,
compatible with the GSI facility during the German ion
beam therapy pilot project and representative of mod-
ern combined-beam facilities, like the Particle Therapy
Center in Marburg. For proton plans spot sizes between
11.0 mm and 5.5 mm were enabled by treatment planning
and delivery with shorter nozzle-to-patient distance than
for carbon ions [18]. These planning settings enabled the
highest available comparability of treatment plans, as they
resulted in proton spot sizes, measured at patient surface,
as close as possible to the corresponding ones of carbon
ions.
In the irradiation raster, the transversal distance
between neighboring spots (pitch) was set to 2 mm for
carbon ion plans and 3 mm for proton plans. A tolerance
of 0.4–1.0 times the spot size was set, allowing the TPS
to place additional raster spots outside the target volume
projection, transversely to the beam, to ensure PTV cov-
erage without the need for high fluence spots at the target
border. For carbon ion plans, a ripple filter was used to
broaden the narrow pristine Bragg peaks and enable an
in-depth peak positioning step of 3 mm [13]. For proton
planning an in-depth peak distance of 2 mm was used.
In the plans of one patient (P03) a bolus of 20 mm of
water-equivalent material was used to ensure coverage
of a tumor section shallower than the penetration depth of
the lowest energy available. The dose grid resolution was
the same of the planning CT.
Dosimetric robustness tests
Rigid positioning setup errors were simulated by intro-
ducing shifts of the irradiation fields with respect to
the CT data and recomputing the dose without plan
reoptimization.
All plans were tested against 52 shifts, divided in two
groups respectively of 3D magnitude 1 mm and 2 mm.
For each magnitude the group represents a complete
enumeration of shifts with components, in the patient’s
coordinate system (LR, AP, SI), either zero or equal
in absolute value. In the figures, individual shifts are
expressed through their magnitude and a triplet, with
the + and - signs indicating the direction of the (equal)
non-zero components. The following formula generates




(x, y, z) | ∃c ∈ R, c > 0, x, y, z ∈ {0,±c},
√
x2 + y2 + z2 ∈ {1, 2}
}
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Data evaluation
The treatment plans were compared in terms of dose
distribution and dose-volume histograms (DVH). For a
quantitative assessment of the dose distribution in the
PTV and CTV the 95% isodose coverage index (V95%) and
the homogeneity index (HI), calculated as the difference
(D2% – D98%), were used [5], along with the PTV confor-
mity index (CI) [19]. To evaluate OAR dose, themaximum
dose (Dmax) was reported for the optic structures and
the near-maximum dose at 1% volume (Dnear-max) for the
brainstem. Visual and quantitative dose distribution anal-
ysis was entirely performed with trip2png [20], developed
at our institution.
To analyze dosimetric plan robustness, the differences
of the index values between the recomputed (shifted)
and the initial plan were employed and denoted in the
following as V95%, HI and D(near-)max respectively.
For selected comparisons and indices, statistical signif-
icance was assessed through a non-parametric, paired-
sample sign test with a significance level of 0.05, using the
R environment for statistical computing [21].
Results
Initial dosimetric quality of treatment plans
The mean (range) prescribed dose was 61.8 (60–63)
Gy(RBE) for carbon ion plans and 66.9 (64–74) Gy(RBE)
for proton plans. The initial (no shift) plans showed com-
parable target coverage for all planning approaches. The
median PTV and CTV V95%, PTV and CTV HI, PTV CI
and OAR D(near-)max values for all planning scenarios are
shown in Table 1. In all carbon ion treatment plans, the
planning objective of PTV V95% ≥ 95.0% was fulfilled,
except in one of the scLR plans, where it was compromised
to 93.1% in order to meet OAR sparing constraints. For
the same reason, for protons the planning objective (PTV
V95% ≥ 95.0%) had to be compromised twice in mcLR
plans (to 94.4% and 90.4%) and once in mcROB plans
(to 93.1%).
Plan robustness
Figure 1 presents carbon ion and proton axial dose distri-
butions of an example patient, as planned and as resulting
from exposure to setup errors of magnitude 1 mm and 2
mm, for various planning scenarios: a plan with multiple-
field optimization and lateral-opposed beam directions
(mcLR) and a plan with multiple-field optimization and
individually chosen, robust beam directions (mcROB).
The lateral-opposed-beam dose distributions for both
particle species show cold spots reaching into the CTV
volume, despite the 2 mm CTV-to-PTV margin, a typical
consequence of particle beam displacement with respect
to a strong tissue density interface. The underdosage
is not present in dose distributions from robust beam
setups.
The corresponding dose-volume histograms of CTV
and chiasm are presented in Figure 2, together with
the DVHs of all other simulated shifts, illustrating the
range of target coverage reduction and OAR involvement
variability.
The changes of carbon ion and proton CTV V95% and
HI induced by selected shifts, across the studied patient
cohort, are shown in Figure 3. Since a shift along the beam
does not introduce any density variation, i.e. any dose per-
turbation, for each pair of setup errors differing only in the
sign of the LR component, only one is shown (positive LR
component), for the sake of figure readability.
In general, setup errors caused a reduction of target
coverage and homogeneity in the dose distributions. For
lateral-opposed carbon ion plans making use of beam
modulation (mcLR), the median reduction in CTV V95%
was up to 0.7 pp and 3.5 pp, for the worst-case shifts of
magnitude 1 mm and 2 mm respectively. In individual
cases, notably stronger coverage deterioration has been
observed, with CTV V95% decreasing by up to 5.1 pp and
9.7 pp respectively. The corresponding values for the pro-
ton plans of the same type were comparable, with median
CTV V95% reduction of at most 0.9 pp (1 mm error)
and 3.4 pp (2 mm error) and respective individual case
reduction of at most 3.2 pp and 11.7 pp.
In order to assess and compare the overall robustness of
treatment plan groups, histograms of the observed CTV
V95%, CTVHI and OAR D(near-)max changes are presented
in Figures 4, 5 and 6.
Comparison of optimizationmodalities
Carbon ion plans
Carbon ion plans introducing OAR sparing constraints
through full intensity-modulation (mcLR) exhibited, in
presence of setup errors, higher losses in target coverage,
in comparison to the unconstrained counterparts. As vis-
ible in Figure 3, these differences in CTV V95% were
only slight in median value (within 1 pp), for all sim-
ulated shifts, while in individual cases they reached 3.7
pp. This reduction of robustness, induced by the mod-
ulation of the irradiation fields, is also reflected in the
histograms in Figure 4, with the predominance of smaller
CTVV95% changes in the unconstrained plans (about 70%
vs. 63% of displacements resulting in V95% smaller than
1 pp in absolute value). Additionally, in about half of the
simulated shifts, the reduction of CTV V95%, induced by
the additional field modulation, was found to be statisti-
cally significant, although the generally low differences in
median value suggest a lack of clinical relevance.
The effect of setup errors on target dose homogene-
ity appeared to be virtually unaffected by the difference
in field modulation. For all simulated shifts, median CTV
HI of mcLR plans oscillated about the corresponding
ucLR values without a clear trend and always below 1 pp
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Table 1 Selectedmedian (range) dosimetric indices of the optimized plans
Planning approach
Dosimetric index Carbon ion plans Proton plans
ucLR scLR mcLR mcROB ucLR mcLR mcROB
PTV V95% 99.2 97.9 98.3 98.3 97.2 95.2 95.8
[ %] (98.3-99.7) (93.1-99.1) (95.0-99.3) (95.2-98.7) (96.0-99.3) (90.4-97.7) (93.1-97.3)
CTV V95% 100.0 99.7 99.8 99.7 99.5 98.8 99.2
[ %] (99.9-100.0) (97.3-100.0) (98.5-100.0) (98.8-100.0) (99.2-99.8) (95.5-99.6) (97.8-100.0)
PTV HI 5.9 7.8 7.7 7.8 11.2 13.9 12.5
[ pp] (4.5-8.1) (6.0-11.1) (5.5-10.3) (6.6-10.8) (6.3-12.9) (9.9-14.9) (9.5-13.8)
CTV HI 4.0 4.8 4.6 5.0 7.9 9.4 8.7
[ pp] (3.4-5.0) (3.6-8.2) (3.7-7.7) (4.5-7.3) (5.1-9.3) (7.0-12.5) (6.3-9.9)
PTV CI 0.85 0.87 0.87 0.86 0.78 0.79 0.78
[−] (0.81-0.91) (0.80-0.91) (0.82-0.91) (0.82-0.89) (0.70-0.88) (0.71-0.87) (0.71-0.84)
Dnear-max brainstem n/a 53.9 52.9 52.2 n/a 61.0 60.2
[Gy(RBE)] (38.8-55.0) (35.6-54.2) (36.9-54.3) (45.5-63.1) (46.3-62.6)
Dmax chiasm n/a 54.0 53.9 53.8 n/a 58.1 59.9
[Gy(RBE)] (0.0-54.2) (0.0-54.1) (52.6-54.1) (0.0-60.1) (59.0-60.2)
Dmax ips. optic nerve n/a 54.0 53.8 53.8 n/a 59.7 60.1
[Gy(RBE)] (0.0-54.2) (0.0-54.2) (40.6-54.1) (0.0-60.3) (50.9-60.4)
Dmax con. optic nerve n/a 42.9 43.3 39.2 n/a 51.2 42.5
[Gy(RBE)] (0.0-54.2) (0.0-54.2) (0.0-53.9) (0.0-60.5) (0.0-59.8)
Abbreviations: CTV clinical target volume, PTV planning target volume, ips ipsilateral, con contralateral, LR lateral-opposed beam setup, ROB robust beam setup,
uc unconstrained mode, sc single-field modulation,mcmultiple-fieldmodulation, pp percentage point, n/a not applicable.
in absolute value. Also the CTVHI histograms in Figure 4
show no distinct effect.
Increased incidence of larger Dmax changes in criti-
cal structures was also observed for constrained plans
(Figure 4). In particular, for the ipsilateral optic nerve
in 16% more of the cases the Dmax change exceeded 2
Gy(RBE) in absolute value. For the contralateral optic
nerve this difference was 6% and for optic chiasm 10%.
The increase in beam modulation almost did not affect
Dnear-max stability of the brainstem: the number of obser-
vations with an absolute deviation larger than 2 Gy(RBE)
varied by less than 4% of the total, between the two
optimization approaches. In the majority of cases under
investigation, the brainstem was abutting the PTV, with
its surface located in the strong dose gradient region for
all planning modalities, rendering Dnear-max subject to
significant changes for all plans.
Regarding scLR treatment plans, even smaller differ-
ences between them and the corresponding mcLR were
observed. Throughout all simulated shifts the variation
in CTV V95% was at most 0.4 pp in median value and
1.3 pp in single cases. Also the smaller deviations in the
histograms (Figure 4) suggest that in practice no differ-
ence in robustness against setup errors exists between the
two constrained planning approaches, at least at the levels
of field modulation required for the indications under
investigation.
Proton plans
For proton plans, the effect of modulation on CTV cov-
erage, in presence of setup errors, was less pronounced
and did not present a clear trend (Figure 3). Also for pro-
tons, median CTV V95% was slightly better preserved in
unconstrained plans, throughout the simulated shifts, but
this was not always true in individual cases. Together with
the small differences in median value, a paired-sample
sign test reported, for almost all investigated shifts, no
statistically significant difference between the two pro-
ton planning approaches. The similar behavior of muLR
and mcLR plans is also confirmed by the respective CTV
V95% histograms in Figure 4.
Median values throughout all simulated setup errors
seem to suggest a better HI preservation in the case of
constrained plans (Figure 3). This is also somewhat vis-
ible in the histogram in Figure 4, where smaller CTV
HI changes appear to be a little more common (4%
of cases more) in constrained than in unconstrained
plans.
With the introduction of modulation, also an incidence
of larger D(near-)max changes for critical structures was
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Figure 1 Examples of setup error effects on dose distributions. For an example patient, (a) carbon ion and (b) proton dose distributions of two
planning approaches (mcLR andmcROB) as planned (0,0,0) and re-computed in presence of positioning errors of 1 mm (0,+,-) and 2 mm (0,0,-). In
the shifts + and - indicate the direction of (equal) non-zero components. Abbreviations: LR – lateral-opposed beam setup, ROB – robust beam setup,
mc – multiple-field modulation.
observed, whichwasmostly pronounced for the ipsilateral
optic nerve (8% cases more exceeding 2 Gy(RBE) in abso-
lute value) and less marked for the other optic nerve, for
the optic chiasm and for the brainstem (respectively 4%,
5% and 5%).
Comparison of beam setups
Carbon ion plans
Carbon ion treatment plans with beam setups selected to
avoid severe density inhomogeneities (mcROB) exhibited,
in presence of setup errors, greater dosimetric stability
than the corresponding lateral-opposed plans (mcLR), in
terms of preservation of both target coverage and dose
homogeneity. Among all simulated shifts, mcROB plans
were affected by CTV V95% loss of at most 2.5 pp in
median value, reaching 6.3 pp in individual cases, which
represents a clear improvement in comparison with the
mcLR plans of the same patient cohort, with respective
values of 4 pp and 9.7 pp. Similarly, for the CTV HI,
mcROB plans presented better median value preservation
(by up to 1.6 pp) and particularly strong worst case
reduction, almost halving the difference.
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Figure 2 Examples of setup error effects on dose-volumehistograms (DVH). For the example patient in Figure 1, CTV and chiasm DVH of
(a) carbon ion and (b) proton treatment plans using two different planning approaches (mcLR andmcROB) as planned and re-computed in
presence of positioning errors. In color the original plan and two setup errors, of 1 mm (0,+,-) and 2 mm (0,0,-), shown in Figure 1. In grey all other
simulated setup errors. In the shifts, + and - indicate the direction of (equal) non-zero components. Abbreviations: CTV – clinical target volume,
LR – lateral-opposed beam setup, ROB – robust beam setup, mc – multiple-field modulation.
While a direct shift-by-shift comparison between the
plans is not applicable, as the influence of each setup
error is specific to irradiation direction, the advantage of
robust over lateral-opposed beam setups is visible in the
histograms in Figure 5 as strong dominance of smaller
changes (below 1 pp in absolute value) in CTV V95%
(16% of cases more) and CTV HI (18% of cases more)
for mcROB plans and in the prolonged tails toward larger
variations formcLR plans.
Also organs at risk benefitted from the greater dosimet-
ric stability, afforded by robust beam selection, in pres-
ence of setup errors. Reduced incidence of larger Dmax
changes, in comparison with the lateral-opposed plans,
was observed for most of the critical structures: the index
deterioration remained below 2 Gy(RBE) in absolute value
in 25% of the shifts more for the chiasm, 11% more for
the contralateral optic nerve and 7% more for the ipsilat-
eral optic nerve. Only for the brainstem, which for nearly
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Figure 3 Population box-and-whiskers plots of CTV dose coverage and homogeneity with detailed comparison of optimization
modalities. Population (a) carbon ion and (b) proton median value (within box), 1st and 3rd quartiles (box) and minimum and maximum
values (whiskers) of CTV V95% and HI for selected setup errors on LR plans with different optimization modalities: uc,mc and sc. In the shifts +
and - indicate the direction of (equal) non-zero components. Abbreviations: CTV – clinical target volume, LR – lateral-opposed beam setup,
uc – unconstrained mode, sc – single-field modulation, mc – multiple-field modulation.
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Figure 4 Population frequency histograms of variations in dosimetric indices for all simulated setup errors and different optimization
modalities. Frequency histograms of the observed CTV V95%, CTV HI and OAR D(near-)max comparing LR treatment plans with different
optimization modalities (uc,mc and sc) for (a) carbon ions and (b) protons. Abbreviations: CTV – clinical target volume, OAR – organ(s) at risk,
LR – lateral-opposed beam setup, uc – unconstrained mode, sc – single-field modulation, mc – multiple-field modulation.
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Figure 5 Population frequency histograms of variations in dosimetric indices for all simulated setup errors and different beam setups.
Frequency histograms of the observed CTV V95%, CTV HI and OAR D(near-)max comparingmc treatment plans adopting LR and ROB beam
setups for (a) carbon ions and (b) protons. Abbreviations: CTV – clinical target volume, OAR – organ(s) at risk, LR – lateral-opposed beam setup,
ROB – robust beam setup,mc – multiple-field modulation.
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Figure 6 Population frequency histograms of variations in dosimetric indices for all simulated setup errors and different ion species.
Frequency histograms of the observed CTV V95%, CTV HI and OAR D(near-)max comparing carbon ion and proton treatment plans with
(a)mcLR and (b)mcROB planning approaches. Abbreviations: CTV – clinical target volume, OAR – organ(s) at risk, LR – lateral-opposed beam setup,
ROB – robust beam setup,mc – multiple-field modulation.
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all patients was in contact with the target dose gradient
region, no considerable improvement in Dnear-max stability
was observed.
Protonplans
In presence of setup errors, proton mcROB treatment
plans achieved, similarly to the equivalent carbon ion
ones, better preservation of target coverage and dose
homogeneity in comparison to plans with a lateral-
opposed beam setup. InmcROB plans, median and worst-
case CTV V95% losses were 2.8 pp and 5.8 pp respectively,
while in the corresponding mcLR plan they were 3.6 pp
and 11.7 pp. HI median and worst-case variations were
instead 3.4 pp and 6 pp for mcROB plans and 3.9 pp
and 14.2 pp for mcLR plans. The dosimetric advantage in
target dose conservation through robust beam configura-
tions is visible in theV95% andHI deterioration histograms
in Figure 5, wheremcROB exhibit a larger number of cases
(respectively 7% and 8%) affected by smaller absolute
changes.
Proton mcROB treatment plans also offered improved
OAR dose stability. In comparison to the correspond-
ing lateral-opposed plans, in a higher number of cases
D(near-)max remained in absolute value within 2 Gy(RBE)
for the contralateral optic nerve (16% of cases more),
ipsilateral optic nerve (9%), optic chiasm (29%) and
brainstem (7%).
Comparison of ion species
The preceding subsections already report data on the
investigated scenarios, for both carbon ions and protons.
Some results of potential interest are better described
through direct comparison of the two ion species, as
presented in Figure 6, for mcLR and mcROB plans,
which both represent clinically valid treatment planning
approaches.
With a lateral-opposed beam setup protons presented
greater dosimetric stability in the target, a result that
is consistent with the lower initial conformity of proton
plans used in this study (Table 1). Use of robust beam
setups reversed this situation, affording greater CTVV95%
reproducibility to carbon ions andmaking the two particle
species practically equal in terms of HI preservation. This
result shows that applying a planning technique aiming
at reducing physical effects of setup errors, like selecting
less inhomogeneous beam paths, brought greater bene-
fit to the particle species with the most conformal dose
distributions. For both mcLR and mcROB plans, protons
showed greater reproducibility of planned OAR dose, in
presence of setup errors, with the greatest advantage for
Dnear-max in the brainstem, that is the OAR closest to the
target dose gradient (Figure 6).
Finally, it should be emphasized that, while in terms of
relative changes, between optimized plans and simulated
delivery with setup errors, protons demonstrated greater
dosimetric stability (i.e. a larger number of smaller
changes) for the majority of investigated indices and plan
types, in terms of absolute dose values carbon ion plans
used for this study remained superior in terms of both
median target coverage and OAR sparing (Table 1).
Discussion
Systematic plan robustness tests, like those presented in
this manuscript, are necessary to understand the mag-
nitude of delivery-time dose uncertainties, in order to
optimize treatment planning methodologies and also to
ensure the selection of the best treatment for individual
patients.
In fact, despite its heavy requirements in terms of time
and computing resources, a procedure based on multi-
ple plan recomputations, similar to the one used in our
study, was reported by Jäckel et al. [7] as part of the clini-
cal patient-specific quality assurance process, for scanned
carbon ion therapy. An alternative measurement-based
method was proposed by Albertini et al. [22], to assess
plan robustness by recording the effects of setup (or range)
uncertainties on a plan delivered to an anthropomorphic
phantom, thus excluding the inaccuracies of analytical
dose computation algorithms, typically employed in clini-
cal planning systems.While this is certainly a considerable
advantage, this approach is of limited applicability to car-
bon ions, for which only the underlying absorbed dose
distribution deterioration can be measured. Furthermore,
relying on the standardized phantom anatomy appears
more suitable a method to compare the influence of
optimization approaches or planning settings for typical
situations, approximated by target volume definition in
the phantom. Instead, as also shown in our study, sig-
nificant variability between the patients may be present,
stemming from the differences between individual target
volumes and anatomical features, as well as their spatial
relation, which emphasizes the importance of conduct-
ing robustness assessments for specific patients (or well-
defined populations) in order to support clinical decision
making.
Alternatively, accurate dose computation on real patient
geometries can be achieved throughMonte Carlo methods,
a particularly interesting option for proton therapy, for
which a dedicated high-performance implementation was
recently demonstrated [23]. For carbon ions, instead,
while novel integrated tools can simplify clinical applica-
tions [24,25], the prolonged computational times must
be weighed against the expected precision gain, espe-
cially in large scale computations. For one of the cases
presented in this manuscript, for instance, Monte Carlo
was employed on a single treatment plan and a sin-
gle recomputation, demonstrating slight discrepancies in
highly-heterogeneous regions and absorbed-dose DVH
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differences in the order of 2% [25], which warrant more
extensive future investigations.
A critical point, when investigating the dosimetric
effects of setup errors, is selecting the range of errors
to simulate. Two approaches have been proposed in the
literature, simulating either a small number of extreme
displacements, representing the worst-case scenarios, or
calculating numerous dose distributions, reflecting the
entire possible range (and probability) of displacements.
Data obtained in our study suggests that the former
may lead to false conclusions, as the worst case is not
known a priori and not always strictly correlated to the
displacements magnitude. More importantly, the worst-
case displacement is not the same for different beam
setups, rendering direct comparisons of limited value. An
example of this is the comparison of a lateral-opposed
beam setup against other beam configurations in pres-
ence of mediolateral shifts, by which the former remains
unaffected.
Therefore, the study presented in this manuscript was
based on massive plan recomputation, with real patient
data and a comprehensive, fine-grained set of simulated
setup errors, and is, to our best knowledge, the first of
this kind investigating multiple aspects, that affect car-
bon ion and proton dosimetric robustness, in skull base
radiotherapy, on a multi-patient cohort.
The only previous study addressing the issue of robust-
ness against setup errors for carbon ion plans, a confer-
ence communication by Ellerbrock et al. [11], reported
an absolute reduction of the CTV V90% by 0–1 pp for
1 mm displacements and 2–4 pp for 2 mm displace-
ments in one patient. While this work, like ours, tested
a broad range of errors, it focused primarily on usability
of IMPT and employed plans with systematically vary-
ing weight of constraints, rather than clinically valid
ones. It should also be noted that, to counterbalance
the computation-time explosion of multiple optimiza-
tions, only absorbed dose computations were performed,
neglecting both the additional field modulation and the
potential compensation effects, introduced by variable
carbon ion RBE. More recently, Hopfgartner et al. [10]
systematically investigated the robustness of proton treat-
ment plans with respect to interfraction setup uncer-
tainties in 7 skull base (and 7 paranasal sinus) tumor
cases for 6 extreme orthogonal displacements, reporting
median CTV V95% reductions of up to about 3 pp. In
contrast to this study, which aimed at quantifying robust-
ness in presence of extreme displacements for simple
and more complex beam setups, selected with sole con-
sideration of critical structure sparing, the goals of our
work included extensive investigation of the robustness
loss due to field modulation as well as its improvement
through avoidance of critical heterogeneities in the beam
channels.
Our results demonstrate that residual repositioning
errors may, in some cases, lead to a significant perturba-
tion of the delivered dose in scanned-beam carbon ion
and proton therapy for skull base tumors (by up to 10
pp for carbon ions and up to 12 pp in proton plans,
in individual cases), which cannot be completely dealt
with by planning target expansion alone. Only rigid setup
errors were simulated, as they represent the predominant
source of targeting uncertainty in skull base treatments,
with magnitudes (1–2 mm) consistent with the precision
reported for modern non-invasive cranial immobilization
devices and patient positioning systems, in terms of resid-
ual setup errors as well as intrafraction motion [2,26-30].
No rotational errors were simulated, as in comparison
to translational displacements, angular deviations cause
smaller effects as established in the preliminary work for
this study [31] and also observed for other indications [8].
The clinical plans (fulfilling OAR constraints) displayed
a slightly reduced robustness, understood as the spec-
trum of variation of dosimetric indexes induced by pres-
ence of simulated setup errors, as compared to plans
prepared without OAR constraints, illustrating the iso-
lated influence of the dose gradients within the individual,
modulated fields. For individual shifts these differences
however seldom reached statistical significance, confirm-
ing the observation by Ellerbrock et al. [11], that the
generally stronger dose gradients at the field edge have
more significant interactions with positioning uncertain-
ties, while internal dose gradients, caused by inhomo-
geneous dose delivery by individual fields, are weaker
and thus have minor influence on the robustness. Addi-
tionally, in carbon ion plans, only minimal differences
were observed between the two modulation approaches
(single- vs. multiple-field optimization). The strength of
the planning constraints, which determines the magni-
tude of field modulation, is likely a factor influencing this
result. In our study, typical dose modulation (defined here
as the ratio between the maximum OAR dose and the
prescription dose) was 0.85. The robustness of treatment
plans where the application of stronger OAR constraints
might be necessary, e.g. for re-irradiations, should be
investigated for each individual case. Further complexity
lies in the potentially large degeneracy of the optimiza-
tion result. It has been demonstrated that dosimetrically
equivalent IMPT plans employing different modulation
strategies may be characterized by differing degrees of
robustness [32].
One of the most interesting applications of robust-
ness tests against an extensive set of setup errors is
the direct comparison, in terms of dosimetric stability,
of different beam-setups. In our study, for a subset of
patients, improved plan robustness, with respect to both
CTV and OAR dose, was demonstrated when using beam
setups avoiding strongly heterogeneous tissue. It should
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be noted that the beam directions for this set of treatment
plans were selected with sole consideration of the density
homogeneity in the beam channels, i.e. not considering
the position of critical structures, which were however
spared through plan optimization (in compliance with the
planning protocol).
Currently, clinical robustness testing of irradiation
setups must be usually carried out by expert personnel,
on a case-by-case basis, evaluating possible tradeoffs with
planning constraints, like OAR sparing. This underlines
the need for automatized tools to support such multi-
criteria, optimal beam setup selection. Verification of the
entrance channel homogeneity through pattern match-
ing techniques, that mimic human analysis, has been
demonstrated a promising approach, which can be easily
combined, through an optimization process, with clinical
constraints, like patient positioning limitations or OAR
involvement [33,34]. Methods have also been proposed
to include robustness in the plan optimization process in
proton therapy [35] or in margin design [36,37], but they
suffer from the limitation of being based on assumed dis-
tributions of positioning errors and do not have, up to
now, widespread clinical application.
Finally, our study presents the first attempt to compare
the dosimetric robustness of treatment plans employing
different ion species. Between protons and carbon ions,
used in our study, differences have been demonstrated in
the basic dose deposition properties, that may be relevant
in their application as therapeutic radiation types [38]. In
our study, we strove to maintain proton and carbon ion
plans as comparable as possible, in both technical (e.g.
using similar raster spot sizes) and clinical terms (e.g.
using comparable planning objectives). Also, for both par-
ticle species plans with two beams were used, as typical in
carbon ion therapy of the skull base and not uncommon in
proton therapy, especially at fixed-nozzle combined facili-
ties [2,15,18]. Yet, in order to achieve clinically acceptable
plans for both particle species, not all planning settings
could be kept strictly equal, which should not be neglected
when interpreting our results. For instance the signifi-
cant beam broadening in matter undergone by protons
required a larger target projection expansion, to achieve
acceptable PTV coverage, and resulted in a lower initial
conformity of the proton plans. While these were com-
parable, in terms of CTV coverage, to those investigated
in a similar study by Hopfgartner et al. [10], it should
be noted that, in our study, realistic proton spot sizes
attainable at synchrotron-based combined ion therapy
facilities were used, which were inferior to the idealized
ones used by Hopfgartner et al. [10]. Additional proton
beams, as often used when a rotating gantry is available,
would have likely improved the initial conformity, but they
would have also altered the robustness, as observed e.g. by
Hopfgartner et al. [10].
Most notably, from a strictly numerical interpretation
of our results, in most of the scenarios considered, in
presence of setup errors protons appear to deviate less
from the planned values, both in CTV coverage and
OAR involvement, with a particular stability advantage for
the brainstem, the organ closest to the target and often
in direct contact with it. This observation could be of
importance in clinical decision-making, e.g. when defin-
ing guidelines and thresholds for image-guided radiother-
apy (IGRT) protocols, and is likely related to the more
pronounced scattering protons undergo, resulting in typi-
cally shallower gradients. Another important observation,
related to potential clinical applications, is that carbon
ion plans, with their higher initial conformity and more
advantageous absolute dosimetric values, received greater
advantage, in terms of target dose reproducibility, through
use of robust beam setups.
Ultimately, purpose of the comparison was not to iden-
tify the best particle species, but rather to demonstrate
how the differences in the physical properties of ions,
and in the clinical applications they enable, may affect
our understanding of robustness issues. In this sense, a
certainly valid general conclusion is that per-indication
studies should be carried out for each ion species and
some care should be used when translating results from
one particle type to another. This is particularly impor-
tant in the current context of combined facilities, where
protons and carbon ions are used for different indica-
tions, and as newer ion species, e.g. oxygen or helium,
are being considered for introduction in clinical particle
therapy [39]. Similarly, where a radiobiological model is
used to compute effective dose, results should not be con-
sidered valid across different models, model versions or
model input parameters [40,41].
When assessing the impact of these results on patient
treatments, one aspect, crucial for the interpretation of
this study, should not be neglected. The application of
the total therapeutic dose is typically fractionated, causing
delivery uncertainties to be statistically smoothed, pro-
vided that they are not systematic. It is therefore advisable
that, for a thorough clinical assessment, a similar study
be conducted in the future, employing e.g. the results
of daily positioning verification data, to assess cumula-
tive dose. Finally, the positioning errors are only one of
many potential delivery-time uncertainties that can affect
the final dose distribution, like range uncertainties [32],
anatomy changes [42], beam fluctuations [43], etc. For
novel techniques, like carbon ion scanned-beam radio-
therapy, the relevance of such uncertainties and of their
interplay remains mostly to be quantified.
Competing interests
The authors declare that they have no competing interests. The authors alone
are responsible for the content and writing of the paper.
Ammazzalorso et al. RadiationOncology 2014, 9:279 Page 15 of 16
http://www.ro-journal.com/content/9/1/279
Authors’ contributions
FA designed the study, performed initial treatment planning, designed the
data evaluation process and managed the study data, authored and managed
the manuscript. UJ co-designed the study, clinically revised the treatment
plans, performed numerical and statistical evaluation and extensively
co-authored the manuscript. REC provided clinical input during study design,
performed patient selection, reviewed treatment plans and reviewed the final
manuscript. WS provided substantial methodological input during study
design and data evaluation and reviewed the final manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This study was supported by a research grant of the University Medical Center
Giessen and Marburg UKGM (Project Number 35/2010 MR) and by the ULICE
project co-funded by the European Commission under FP7 (Grant Agreement
Number 228436). The authors would like to acknowledge Dr. M. Krämer for
enabling the TRiP98 computations, Dr. G. Iancu for providing the proton base
data, Dr. A. Wittig for her help during the patient data retrieval phase and free
(as in freedom) software for making the study just possible.
Received: 16 May 2014 Accepted: 23 September 2014
References
1. Schulz-Ertner D, Tsujii H: Particle radiation therapy using proton and
heavier ion beams. J Clin Oncol 2007, 25:953–964.
2. Orecchia R, Vitolo V, Fiore M. R, Fossati P, Iannalfi A, Vischioni B, Srivastava
A, Tuan J, Ciocca M, Molinelli S, Mirandola A, Vilches G, Mairani A, Tagaste
B, Riboldi M, Fontana G, Baroni G, Rossi S, Krengli M: Proton beam
radiotherapy: report of the first ten patients treated at the “Centro
Nazionale di Adroterapia Oncologica (CNAO)” for skull base and
spine tumours. Radiol med 2014, 119:277–282.
3. Lomax AJ: Intensity modulated proton therapy and its sensitivity to
treatment uncertainties 2: the potential effects of inter-fraction and
inter-field motions. Phys Med Biol 2008, 53:1043–1056.
4. Krämer M, Scholz M: Treatment planning for heavy-ion radiotherapy:
calculation and optimization of biologically effective dose.
Phys Med Biol 2000, 45:3319–3330.
5. International Commission on Radiation Units and Measurements (ICRU):
ICRU Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy.
Bethesda, MD: ICRU; 2007.
6. Cantone MC, Ciocca M, Dionisi F, Fossati P, Lorentini S, Krengli M, Molinelli
S, Orecchia R, Schwarz M, Veronese I, Vitolo V: Application of failure
mode and effects analysis to treatment planning in scanned proton
beam radiotherapy. Radiat Oncol 2013, 8:127.
7. Jäkel O, Krämer M, Karger CP, Debus J: Treatment planning for heavy
ion radiotherapy: clinical implementation and application.
Phys Med Biol 2001, 46:1101–1116.
8. Meyer J, Bluett J, Amos R, Levy L, Choi S, Nguyen QN, Zhu XR, Gillin M,
Lee A: Spot scanning proton beam therapy for prostate cancer:
treatment planning technique and analysis of consequences of
rotational and translational alignment errors. Int J Radiat Oncol
Biol Phys 2010, 78:428–434.
9. Jelen U, Ammazzalorso F, Chanrion MA, Gräf S, Zink K, Engenhart-Cabillic
R, Wittig A: Robustness against interfraction prostate movement in
scanned ion beam radiation therapy. Int J Radiat Oncol Biol Phys 2012,
84:257–262.
10. Hopfgartner J, Stock M, Knäusl B, Georg D: Robustness of IMPT
treatment plans with respect to inter-fractional set-up
uncertainties: Impact of various beam arrangements for cranial
targets. Acta Oncol 2013, 52:570–579.
11. Ellerbrock M, Jäkel O, Krämer M, Nikoghosyan A, Schulz-Ertner D, Karger
CP, Ackermann B, Heeg P, Debus J: Clinical implementation of
intensity modulated radiotherapy using carbon ions [abstract].
Int J Radiat Oncol Biol Phys 2008, 72(Suppl 1):592.
12. Haberer T, Becher W, Schardt D, Kraft G:Magnetic scanning system for
heavy ion therapy. Nucl InstrumMethods A 1993, 330:296–305.
13. Krämer M, Jäkel O, Haberer T, Kraft G, Schardt D, Weber U: Treatment
planning for heavy-ion radiotherapy: physical beammodeling and
dose optimization. Phys Med Biol 2000, 45:3299–3317.
14. TRiP98 Online Documentation [http://bio.gsi.de/DOCS/TRiP98/DOCS/
trip98.html]
15. Nikoghosyan AV, Karapanagiotou-Schenkel I, Münter MW, Jensen AD,
Combs SE, Debus J: Randomised trial of proton vs and carbon ion
radiation therapy in patients with chordoma of the skull base,
clinical phase III study HIT-1-Study. BMC Cancer 2010, 10:607.
16. Nikoghosyan AV, Rauch G, Münter MW, Jensen AD, Combs SE, Kieser M,
Debus J: Randomised trial of proton vs and carbon ion radiation
therapy in patients with low and intermediate grade
chondrosarcoma of the skull base, clinical phase III study.
BMC Cancer 2010, 10:606.
17. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rut HP, Schuller JC,
Pedroni E, Goitein G: Effectiveness and safety of spot scanning proton
radiation therapy for chordomas and chondrosarcomas of the skull
base: first long-term report. Int J Radiat Oncol Biol Phys 2009,
75:1111–1118.
18. Jelen U, Bubula ME, Ammazzalorso F, Engenhart-Cabillic R, Weber U,
Wittig A: Dosimetric impact of reduced nozzle-to-isocenter distance
in intensity-modulated proton therapy of intracranial tumors in
combined proton-carbon fixed-nozzle treatment facilities.
Radiat Oncol 2013, 8:218.
19. Paddick I: A simple scoring ratio to index the conformity of
radiosurgical treatment plans. J Neurosurg 2000, 92(Suppl 3):219–222.
20. Ammazzalorso F, Chanrion MA, Graef S, Jelen U: A free software display
and analysis tool for photon and particle radiotherapy dose
distributions [abstract]. Proceedings to the 52nd AnnualMeeting for
the Particle Therapy Cooperative Group (PTCOG). Int J Particle Ther
2014, 1:312–313.
21. R Development Core Team: R: A Language and Environment for Statistical
Computing. Vienna: The R Foundation for Statistical Computing; 2012.
ISBN 3-900051-07-0. [http://www.R-project.org/].
22. Albertini F, Casiraghi M, Lorentini S, Rombi B, Lomax A: Experimental
verification of IMPT treatment plans in an anthropomorphic
phantom in the presence of delivery uncertainties. Phys Med Biol
2011, 56:4415–4431.
23. Jia X, Schümann J, Paganetti H, Jiang SB: GPU-based fast Monte Carlo
dose calculation for proton therapy. PhysMed Biol 2012, 57:7783–7797.
24. Tessonnier T, Mairani A, Cappucci F, Mirandola A, Freixas GV, Molinelli S,
Donetti M, Ciocca M: Development and application of tools for Monte
Carlo based simulations in a particle beam radiotherapy facility.
Appl Radiat Isot 2014, 83:155–158.
25. Jelen U, Radon M, Santiago A, Wittig A, Ammazzalorso F: AMonte Carlo
tool for raster-scanning particle therapy dose computation.
J Phys Conf Ser 2014, 489:012013.
26. Schulte RW, Fargo RA, Meinass HJ, Slater JD, Slater JM: Analysis of head
motion prior to and during proton beam therapy. Int J Radiat Oncol
Biol Phys 2000, 47:1105–1110.
27. Bolsi A, Lomax AJ, Pedroni E, Goitein G, Hug E: Experiences at the Paul
Scherrer Institute with a remote patient positioning procedure for
high-throughput proton radiation therapy. Int J Radiat Oncol Biol Phys
2008, 71:1581–1590.
28. Jelen U: Recommendations for organ depending optimized fixation
systems. Deliverable D.JRA 5.1. EU-Project ULICE (GA no. 228436), 2011.
[http://ulice.web.cern.ch/ULICE/].
29. Jensen AD, Winter M, Kuhn SP, Debus J, Nairz O, Münter MW:
Robotic-based carbon ion therapy and patient positioning in 6
degrees of freedom: setup accuracy of two standard
immobilization devices used in carbon ion therapy and IMRT.
Radiat Oncol 2012, 7:51.
30. Nairz O, Winter M, Heeg P, Jäkel O: Accuracy of robotic patient
positioners used in ion beam therapy. Radiat Oncol 2013, 8:124.
31. Ammazzalorso F, Jelen U, Strassmann G, Engenhart-Cabillic R: Influence
of the choice of beam directions on the dosimetric quality and
robustness of heavy ion radiotherapy plans [abstract]. In Proceedings
of the Heavy Ions in Therapy and Space Symposium: 6–10 July 2009; Cologne,
2009:74.
32. Lomax AJ: Intensity modulated proton therapy and its sensitivity to
treatment uncertainties: 1. the potential effects of calculational
uncertainties. Phys Med Biol 2008, 53:1027–1042.
33. Ammazzalorso F, Jelen U, Krämer M, Strassmann G, Engenhart-Cabillic R:
Validation of a homogeneity index for the optimal selection of
Ammazzalorso et al. Radiation Oncology 2014, 9:279 Page 16 of 16
http://www.ro-journal.com/content/9/1/279
robust beam configurations in heavy ion radiotherapy planning
[abstract]. Radiother Oncol 2009, 92(Suppl 1):109.
34. Ammazzalorso F, Bednarz T, Jelen U: GPU-accelerated automatic
identification of robust beam setups for proton and carbon-ion
radiotherapy. J Phys Conf Ser 2014, 489:012043.
35. Unkelbach J, Bortfeld T, Martin B. C, Soukup M: Reducing the sensitivity
of IMPT treatment plans to setup errors and range uncertainties via
probabilistic treatment planning.Med Phys 2009, 39:149–163.
36. Park PC, Zhu XR, Lee AK, Sahoo N, Melancon AD, Zhang L, Dong L:
A beam-specific planning target volume (PTV) design for proton
therapy to account for setup and range uncertainties. Int J Radiat
Oncol Biol Phys 2012, 82:329–336.
37. Cabal GA, Jäkel O:Dynamic target definition: a novel approach for PTV
definition in ion beam therapy. Radiother Oncol 2013, 107:227–233.
38. Weber U, Kraft G: Comparison of carbon ions versus protons.
Cancer J 2009, 15:325–332.
39. Fuchs H, Strobele J, Schreiner T, Hirtl A, Georg D: A pencil beam
algorithm for helium ion beam therapy.Med Phys 2012, 39:6726–6737.
40. Grün R, Friedrich T, Elsässer T, Krämer M, Zink K, Karger CP, Durante M,
Engenhart-Cabillic R, Scholz M: Impact of enhancements in the local
effect model (LEM) on the predicted RBE-weighted target dose
distribution in carbon ion therapy. Phys Med Biol 2012, 57:7261–7274.
41. Chanrion M-A, Sauerwein W, Jelen U, Wittig A, Engenhart-Cabillic R,
Beuve M: The influence of the local effect model parameters on the
prediction of the tumor control probability for prostate cancer.
Phys Med Biol 2014, 59(12):3019–3040.
42. Lassen-Ramshad Y, Vestergaard A, Muren LP, Høyer M, Petersen JB: Plan
robustness in proton beam therapy of a childhood brain tumour.
Acta Oncol 2011, 50:791–796.
43. Chanrion MA, Ammazzalorso F, Wittig A, Engenhart-Cabillic R, Jelen U:
Dosimetric consequences of pencil beamwidth variations in
scanned beam particle therapy. Phys Med Biol 2013, 58:3979–3993.
doi:10.1186/s13014-014-0279-2
Cite this article as: Ammazzalorso et al.: Dosimetric robustness against
setup errors in charged particle radiotherapy of skull base tumors.
RadiationOncology 2014 9:279.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
